Ceftazidime
Sold as Orzid, Keftaz, Ceftazidime ascendis, Ceptizid, Ceftazidime fresenius, Auro-ceftazidime, Aurizef, Rezidime, Taziject, Fortum
(6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Drag to rotate. Structure from PubChem CID 5481173.
Background
Registration
- Applicants
- 9
- Registrations
- 27
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pfizer Laboratories (Pty) Ltd | Orzid | 2 g | 410873 | S4 | None |
| Trinity Pharma (Pty) Ltd | Keftaz, Ceptizid | 0,5 g, 1,0 g, 1 g, 2,0 g, 2 g, 500 mg | 410918, 410919, 410920, 420079, 420080, 420081 | S4 | None |
| Ascendis Pharma (Pty) Ltd | Ceftazidime ascendis | 0,5 g, 2,0 g | 410921, 410923 | S4 | None |
| Oethmaan Biosims (Pty) Ltd | Ceftazidime ascendis | 1,0 g | 410922 | S4 | None |
| Fresenius Kabi South Africa (Pty) Ltd | Ceftazidime fresenius | 000 mg 1, 000 mg 2, 500 mg | 430553, 430554, 430555 | S4 | None |
| Aurogen South Africa (Pty) Ltd6 of 8 cancelled | Auro-ceftazidime, Aurizef | 1,0 g, 2,0 g, 250 mg, 500 mg | 431026, 431027, 431028, 431029, 431035, 431036, 431037, 431038 | S4 | None |
| Resmed healthcare | Rezidime | 1000, 2000 | A380632, A380634 | S4 | None |
| Acino Pharma (Pty) Ltd | Taziject | 0,5 G, 1,0 G, 2 G | A390125, A390126, A390127 | S4 | None |
| Sekpharma (Pty) LtdCancelled | Fortum | 250 mg | W0334 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Orzid 2 g EACH VIAL CONTAINS CEFTAZIDIME 2,0 g | 2 g | 41087341/20.1.1/0873 | Registered | S4 | None |
| Keftaz 0,5 g EACH VIAL CONTAINS CEFTAZIDIME 0,5 g | 0,5 g | 41091841/20.1.1/0918 | Registered | S4 | None |
| Keftaz 1,0 g EACH VIAL CONTAINS CEFTAZIDIME 1,0 g | 1,0 g | 41091941/20.1.1/0919 | Registered | S4 | None |
| Keftaz 2,0 g EACH VIAL CONTAINS CEFTAZIDIME 2,0 g | 2,0 g | 41092041/20.1.1/0920 | Registered | S4 | None |
| Ceftazidime 0,5 g ascendis EACH VIAL CONTAINS CEFTAZIDIME 0,5 g | 0,5 g | 41092141/20.1.1/0921 | Registered | S4 | None |
| Ceftazidime ascendis 1,0 g EACH VIAL CONTAINS CEFTAZIDIME 1,0 g | 1,0 g | 41092241/20.1.1/0922 | Registered | S4 | None |
| Ceftazidime 2,0 g ascendis EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 2,0 g | 2,0 g | 41092341/20.1.1/0923 | Registered | S4 | None |
| Ceptizid 500 MG EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 500,0 mg | 500 mg | 42007942/20.1.1/0079 | Registered | S4 | None |
| Ceptizid 1 g EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 1,0 g | 1 g | 42008042/20.1.1/0080 | Registered | S4 | None |
| Ceptizid 2 g EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 2,0 g | 2 g | 42008142/20.1.1/0081 | Registered | S4 | None |
| Ceftazidime 500 MG fresenius EACH VIAL CONTAINS CEFTAZIDIME 500,0 mg | 500 mg | 43055343/20.1.1/0553 | Registered | S4 | None |
| Ceftazidime 1 000 MG fresenius EACH VIAL CONTAINS CEFTAZIDIME 1000,0 mg | 000 mg 1 | 43055443/20.1.1/0554 | Registered | S4 | None |
| Ceftazidime 2 000 MG fresenius EACH VIAL CONTAINS CEFTAZIDIME 2000,0 mg | 000 mg 2 | 43055543/20.1.1/0555 | Registered | S4 | None |
| Auro-ceftazidime 250 MG EACH VIAL CONTAINS CEFTAZIDIME 250,0 mg | 250 mg | 43102643/20.1.1/1026 | Cancelled | S4 | None |
| Auro-ceftazidime 500 MG EACH VIAL CONTAINS CEFTAZIDIME 500,0 mg | 500 mg | 43102743/20.1.1/1027 | Cancelled | S4 | None |
| Auro-ceftazidime 1,0 g EACH VIAL CONTAINS CEFTAZIDIME 1,0 g | 1,0 g | 43102843/20.1.1/1028 | Registered | S4 | None |
| Auro-ceftazidime 2,0 g EACH VIAL CONTAINS CEFTAZIDIME 2,0 g | 2,0 g | 43102943/20.1.1/1029 | Registered | S4 | None |
| Aurizef 250 MG EACH VIAL CONTAINS CEFTAZIDIME 250,0 mg | 250 mg | 43103543/20.1.1/1035 | Cancelled | S4 | None |
| Aurizef 500 MG EACH VIAL CONTAINS CEFTAZIDIME 500,0 mg | 500 mg | 43103643/20.1.1/1036 | Cancelled | S4 | None |
| Aurizef 1,0 g EACH VIAL CONTAINS :CEFTAZIDIME 1,0 g | 1,0 g | 43103743/20.1.1/1037 | Cancelled | S4 | None |
| Aurizef 2,0 g EACH VIAL CONTAINS: CEFTAZIDIME 2,0 g | 2,0 g | 43103843/20.1.1/1038 | Cancelled | S4 | None |
| Rezidime 1000 injection EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 1,0 g | 1000Injection | A380632A38/20.1.1/0632 | Registered | S4 | None |
| Rezidime 2000 injection EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 2,0 g | 2000Injection | A380634A38/20.1.1/0634 | Registered | S4 | None |
| Taziject 0,5 g EACH VIAL CONTAINS :CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 0,5 g | 0,5 G | A390125A39/20.1.1/0125 | Registered | S4 | None |
| Taziject 1,0 g EACH VIAL CONTAINS : CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 1,0 g | 1,0 G | A390126A39/20.1.1/0126 | Registered | S4 | None |
| Taziject 2 g EACH VIAL CONTAINS: CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 2,0 g | 2 G | A390127A39/20.1.1/0127 | Registered | S4 | None |
| Fortum 250 MG for injection EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO CEFTAZIDIME 250 mg | 250 mgFor injection | W0334W/20.1.1/334 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Ceftazidime
S4: Ceftazidime
Consolidated Schedules 06 July 2026, line 5745
Pharmacological class: Broad and medium spectrum antibiotics. (class 20.1.1)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.